NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
MRG address issues involving access to care, chronic disease management, patient adherence & compliance to doctors orders, and frees up clinicians time through leveraging...
Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...
In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA...
